Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 10Esophageal Neoplasms 5Colorectal Neoplasms 5Rectal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma Of Esophagus 4Sarcoma 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neoplasms 2Melanoma 2Vomiting 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Peritoneal Metastases From Gastric Cancer 1Peritoneal Metastases From Colorectal Cancer 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Nausea 1Multiple Myeloma 1Malignant mesenchymal tumor 1

Interventions

pembrolizumab 51Ipilimumab 49Cyclophosphamide 43Nivolumab 40aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10spartalizumab 9cobimetinib 9binimetinib 9Radiotherapy 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Melanoma × Neoadjuvant Therapy × Clear all
NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Sandoz

Phase 3 Terminated
52 enrolled
Dermatologic

Melanoma

NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡